Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial

CheckMate 459: Health-related quality of life (HRQoL) in a randomized, multicenter phase III study of nivolumab (NIVO) versus sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC).

(2020) Julien Edeline et al.   JOURNAL OF CLINICAL ONCOLOGY

International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomised controlled trials: recommendations of the SISAQOL Consortium

(2020) Corneel Coens et al.   LANCET ONCOLOGY

Health-related quality of life in cancer patients treated with immune checkpoint inhibitors: A systematic review on reporting of methods in randomized controlled trials

(2020) Stéphane Faury et al.   PLoS One

Ramucirumab in elderly patients with hepatocellular carcinoma and elevated alpha‐fetoprotein after sorafenib in REACH and REACH‐2

(2020) Masatoshi Kudo et al.   LIVER INTERNATIONAL

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

(2020) Richard S. Finn et al.   NEW ENGLAND JOURNAL OF MEDICINE

O-8 Atezolizumab + bevacizumab vs sorafenib for unresectable hepatocellular carcinoma: Results from older adults enrolled in IMbrave150

(2020) D. Li et al.   ANNALS OF ONCOLOGY

Health‐related quality‐of‐life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma: KEYNOTE‐240

(2020) Baek‐Yeol Ryoo et al.   CANCER

Investigating Potential Bias in Patient-Reported Outcomes in Open-label Cancer Trials

(2019) Jessica K. Roydhouse et al.   JAMA Oncology

Quality-adjusted life years assessment using cabozantinib for patients with advanced hepatocellular carcinoma (aHCC) in the CELESTIAL trial.

(2019) Ghassan K. Abou-Alfa et al.   JOURNAL OF CLINICAL ONCOLOGY

Patient reported outcomes in anti-PD-1/PD-L1 inhibitor immunotherapy registration trials: FDA analysis of data submitted and future directions

(2019) Bellinda L King-Kallimanis et al.   Clinical Trials

Current Treatment Landscape for Advanced Hepatocellular Carcinoma: Patient Outcomes and the Impact on Quality of Life

(2019) Daneng Li et al.   Cancers

Prognostic value of patient-reported outcomes from international randomised clinical trials on cancer: a systematic review

(2019) Justyna Mierzynska et al.   LANCET ONCOLOGY

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

(2018) Masatoshi Kudo et al.   LANCET

Trustworthiness of Patient-Reported Outcomes in Unblinded Cancer Clinical Trials

(2017) Thomas M. Atkinson et al.   JAMA Oncology

Under-reporting of harm in clinical trials

(2016) Bostjan Seruga et al.   LANCET ONCOLOGY

Reporting of Patient-Reported Outcomes in Randomized Trials

(2013) Melanie Calvert et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Evidence-based guidelines for interpreting change scores for the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30

(2012) K. Cocks et al.   EUROPEAN JOURNAL OF CANCER

The added value of quality of life (QoL) for prognosis of overall survival in patients with palliative hepatocellular carcinoma

(2012) Momar Diouf et al.   JOURNAL OF HEPATOLOGY

International cross-cultural field validation of an European Organization for Research and Treatment of Cancer questionnaire module for patients with primary liver cancer, the European Organization for Research and Treatment of Cancer quality-of-life ques

(2011) Wei-Chu Chie et al.   HEPATOLOGY

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE